Big Boozers Attract Big Pharma
By Kate Kelland | Reuters.com
Does this sound like anyone you know? Darryl is 35, has a steady job, a stable home and good marriage, enjoys a few beers in front of the TV most nights -- doesnít have what most people would call a drink problem.
In the United States alone there are probably around 36 million Darryls, according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which created the character, played by an actor on its website to help train doctors.
He doesnít exercise as much as maybe he should so heís a little overweight. At an average of four drinks a day, he is no alcoholic: but some experts now see him as a high-risk drinker and say he could succumb to "alcohol use disorder."
Millions more people across the developed world -- who drink a few glasses of wine every night after work or look forward to three nights of repeated shots with chasers on the weekends -- may today be adding up to a major health and social problem.
Could there be a pill to help them?
A reassessment of the nature of addiction, particularly to alcohol, is starting to pique Big Pharmaís interest. For years the industry has been lukewarm, assuming either that finding a cure for alcoholism is impossible, or else that the target market -- homeless drop-outs, jobless bums and convicted drink drivers -- would not make for great returns.
Now changing western attitudes and cheap supermarket-supplied alcohol have made excessive drinking normal, including among the middle classes. Some experts predict the arrival soon of a new generation of drugs to help everyday drinkers.
"The potential market for medications that can be prescribed for these functional alcoholics is huge," said Mark Willenbring, an addiction expert and psychiatrist in the United States.
Just as with depression treatment 30 years ago, he says alcoholism research could be approaching a "Prozac moment" when it will become more natural, and more acceptable, for doctors to prescribe a pill to help people through a bad patch.
There are already drugs available to treat alcoholism, but their effects vary widely. As scientistsí understanding of what alcohol does to our brain functions deepens, so, potentially, does the range of possible treatments.
Data from Thomson Pharma, a ThomsonReuters company that monitors the drug industry, show there are 24 drugs in development for alcoholism, including around 10 or more in mid-stage trials.
BIG BOOZERS ATTRACT BIG PHARMA
Drug giants Merck and Eli Lilly are the biggest hitters stepping up to the plate at the moment: each is pursuing two possible drugs through mid-stage human trials for treating alcoholism.
Biotech firm Alkermes is also very active in this area, with three drugs in development -- two new compounds, and the third a new format of an existing medicine.
As is often the case when drugmakers show renewed interest in an expanding concern, critics may accuse the firms of seeking to create a "new disease" to generate a market for otherwise unnecessary medicines.
But others argue the outcome could prove a lifeline to millions whose drinking presents a risk to their health, and a big bill to society.
"They donít need the intensity of treatment that more severe cases do," said Willenbring. "They donít need to go to alcoholics anonymous for the rest of their lives, they can respond well to some medication and brief behavioral support."
Alcohol and its consequences kill 2.3 million people a year around the world, according to the World Health Organization: that amounts to 3.8 percent of all deaths, ranking drink just below unsafe sex and just above malnutrition in the top 10 causes of death.
When it comes to the burden of disease caused by alcohol, the evidence against drink really stacks up.
As well as contributing to traumatic death and injury in car crashes and other accidents, alcohol is associated with chronic liver disease, many cancers, acute alcohol poisoning, fetal alcohol syndrome and heart disease -- which is itself the No. 1 killer of men and women in industrialized nations.
"Here in the U.S. we have at least 18 million adults who suffer from alcohol use disorder, and probably twice that many who are high-risk drinkers who donít have a diagnosis. We also have roughly 7.5 million adolescents who are binge drinkers, and at least a 1.5 million who are alcohol dependent," said Raye Litten, the NIAAAís chief of medications development.
"Thatís quite a market -- and it is intriguing to large pharmaceutical companies."
In Britain and other parts of Europe, the need may even be greater. Almost a quarter of Britons -- 33 percent of men and 16 percent of women -- are hazardous drinkers, and binge-drinking and its consequences are daily fare for newspaper headline writers and the politicians who must respond to them.
"The toll of alcohol-abuse-fueled aberrant behaviors, from interfamilial violence to slaughter on the highways, wreaks havoc in a scope and intensity that is leagues ahead of all illegal drugs put together," wrote Harry Tracy, a psychologist and publisher of NeuroInvestment, a monthly publication specializing in central nervous system disorders, in a recent report.
DRUGS -- THE OLD AND THE NEW
The race to find more effective drugs is among the hottest areas in alcoholism research, according to the NIAAAís Litten. Of those available so far, none comes close to being a "magic pill" for drunks, or even high-risk drinkers.
Naltrexone, which cuts the desire to drink by blocking the brainís opioid receptors, has been around for years. Disulphiram works on the enzymes that metabolise alcohol to make users feel awful if they drink, while acamprosate is thought to ease withdrawal symptoms such as anxiety and insomnia.
The problem is that one drug can work well in some people, yet have virtually no effect on others. Some make people feel so bad they stop taking them and go back to the bottle.
Of the potential new drugs tracked by Thomson Pharma, many are in very early experimental stages, and given the slow and uncertain pace of drug development it could be a decade or more before something -- if anything -- comes of them.
Those in clinical trials have a 30 percent likelihood of approval rating on BioMedTracker, an analysis tool from Sagient Research, which also works in partnership with Thomson Pharma. Thatís average for a drug at that stage.
Yet addiction experts are encouraged -- not least by progress in what scientists know about alcohol what it does to the brain.
"In the alcohol field over the past 10 years, what weíve found is that itís not just one neurotransmitter system, itís multiple neurotransmitter systems that are involved in alcohol-seeking and drinking behavior," said Litten.
"Because of that, researchers are looking at a variety of sites in the brain and coming up with new types of medications to be tested."
Eli Lillyís OpRA II drug targets the brainís opioid receptors, as does Naltrexone, but neither Lilly nor Merck has disclosed the targets for their other experimental drugs. Alkermesís three projects are all aimed at opioid receptors.
A couple of firms, AstraZeneca and Transcept Pharma, are looking at compounds that hit dopamine receptors -- the "reward" pathway in the brain.
Another possibility showing early promise is topiramate, a medicine which hits multiple sites in the brain and is used in epilepsy and migraine treatment. It has shown some ability to cut alcohol intake in heavy drinkers in a small clinical trial.
And other scientists, like Colin Drummond at the National Addiction Center and Britainís Institute of Psychiatry in London, are focusing on the brainís stress pathways.
He is about to start a small experiment with mifepristone, which researchers hope may be able to reduce the extreme levels of the stress hormone cortisol released in the brain when alcoholics quit drinking.
"Weíre going to start a trial where we will give it to alcoholic patients who come in for detox, with a view to reducing the brain effects of withdrawal," he told Reuters.
Article from: Reuters.com
Howard Martin - Heartmath Institute, Heart Based Living & The Global Coherence Initiative
Scott Tips - Codex Alimentarius Update Victory, Nutrient Reference Values & Swine Flu
Kevin P Miller - Generation Rx, SSRIís & Happy Pills
Kevin P Miller - Pharmaceutical Control, School Shootings & Psychotropic Drugs
Dr. Ann Blake-Tracy - The Danger of SSRIís (Antidepressants)
Antidepressants Now MOST Prescribed Drug Of All
Psychiatry and the Schools: Mental Hygiene in the 21 st Century
Bush To Screen Everyone For íMental Illnessí
New UK Mental Health Laws to enforced Detention and Medication
The Great Flu Game, Brought to You by Big Pharma
Big Pharma Is in a Frenzy to Bring Cannabis-Based Medicines to Market
Widespread Ghostwriting of Drug Trials Means "Scientific" Credibility of Pharmaceutical Industry is a Sham
Shocking Facts About the Pharmaceutical Industry
Latest News from our Front Page
Stephen Hawking: humanity needs to live in space or die out, physicist warns via hologram
Humans should go and live in space within the next 1,000 years, or it will die out, Stephen Hawking has warned.
"We must continue to go into space for the future of humanity," Mr Hawking said. "I don't think we will survive another 1,000 years without escaping beyond our fragile planet."
Hawking issued the warning during one of two talks at the ...
What's wrong with the Swedes - and so many other Whites?
Another in the unending list of suicidal behavior by Swedes, this one by Cecilia Wilkstr√∂m, a Member of the European Parliament for the center-right (!) Liberal Party, who is concerned about the recent drownings in the Mediterranean of Africans attempting to invade Europe. Note that, once again, the Holocaust is front and center stage as a paradigm requiring Westerners to ...
Scenes of Chaos in Baltimore
A largely peaceful protest over the death of Freddie Gray, a 25-year-old black man who suffered a spinal cord injury in police custody, gave way to scattered scenes of chaos here on Saturday night, as demonstrators smashed a downtown storefront window, threw rocks and bottles and damaged police cruisers, while officers in riot gear broke up skirmishes and made 12 ...
MSNBC Guest: "You Don't Have to Have a White Person Around to Have White Supremacy Play Out"
What makes the academic study of ‚Äúwhite supremacy‚ÄĚ and ‚Äúwhite privilege‚ÄĚ so perfect for racialists is that it requires absolutely no parameters of study. There are no standards of proof. There is no way any claims can be vetted in peer-reviewed journals because the ‚Äúevidence‚ÄĚ can be explained by other factors. Anything and everything can be pointed to as being ...
Immigration, World Poverty and Gumballs
Immigration - Global humanitarian reasons for current U.S. immigration are tested in this updated version of immigration author and journalist Roy Beck's colorful presentation of data from the World Bank and U.S. Census Bureau. The 1996 version of this immigration gumballs presentation has been one of the most viewed immigration policy presentations on the internet.
Presented by immigration author/journalist Roy Beck
|More News » |